DE10231655A1 - Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung - Google Patents
Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung Download PDFInfo
- Publication number
- DE10231655A1 DE10231655A1 DE10231655A DE10231655A DE10231655A1 DE 10231655 A1 DE10231655 A1 DE 10231655A1 DE 10231655 A DE10231655 A DE 10231655A DE 10231655 A DE10231655 A DE 10231655A DE 10231655 A1 DE10231655 A1 DE 10231655A1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- lew
- taiz
- monocytes
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000001939 inductive effect Effects 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 241000282414 Homo sapiens Species 0.000 claims abstract description 20
- 238000001514 detection method Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 165
- 210000001616 monocyte Anatomy 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 44
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 31
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 31
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 16
- 239000012894 fetal calf serum Substances 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000012595 freezing medium Substances 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 description 51
- 210000002216 heart Anatomy 0.000 description 50
- 241000700159 Rattus Species 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 36
- 238000002054 transplantation Methods 0.000 description 35
- 230000000638 stimulation Effects 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 239000002609 medium Substances 0.000 description 26
- 230000007774 longterm Effects 0.000 description 25
- 206010068051 Chimerism Diseases 0.000 description 24
- 229930105110 Cyclosporin A Natural products 0.000 description 22
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 22
- 108010036949 Cyclosporine Proteins 0.000 description 22
- 229960001265 ciclosporin Drugs 0.000 description 22
- 230000002980 postoperative effect Effects 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 13
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 13
- 241000282898 Sus scrofa Species 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000000735 allogeneic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 239000003018 immunosuppressive agent Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000009329 Graft vs Host Disease Diseases 0.000 description 7
- 229960002170 azathioprine Drugs 0.000 description 7
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 208000024908 graft versus host disease Diseases 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000003750 conditioning effect Effects 0.000 description 6
- 229940044627 gamma-interferon Drugs 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 241000282887 Suidae Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229940124589 immunosuppressive drug Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 238000009399 inbreeding Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- IJSMFQNTEUNRPY-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-5-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC=C(N=C=S)C=C1C([O-])=O IJSMFQNTEUNRPY-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011066 ex-situ storage Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- JWYQQWMDIXSRTH-UHFFFAOYSA-M sodium;hydroxy oxido hydrogen phosphate Chemical compound [Na+].OOP([O-])(=O)OO JWYQQWMDIXSRTH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (32)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10231655A DE10231655A1 (de) | 2002-07-12 | 2002-07-12 | Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung |
| US10/520,931 US20060286670A1 (en) | 2002-07-12 | 2003-07-11 | Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| DK03763823T DK1492869T3 (da) | 2002-07-12 | 2003-07-11 | Transplantataccept-inducerende celler af monocytisk oprindelse, deres fremstilling og anvendelse |
| IL16602103A IL166021A0 (en) | 2002-07-12 | 2003-07-11 | Trabsolant acceptance inducing cells of monocytic origin and their preparation and use |
| DE60302231T DE60302231T2 (de) | 2002-07-12 | 2003-07-11 | Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung |
| CNB038215748A CN100523176C (zh) | 2002-07-12 | 2003-07-11 | 单核细胞起源的移植物接纳诱导性细胞及其制备和用途 |
| DK05009317T DK1557462T3 (da) | 2002-07-12 | 2003-07-11 | Transplantataccept-inducerende celler af monocytisk oprindelse, deres fremstilling og anvendelse |
| BR0312693-5A BR0312693A (pt) | 2002-07-12 | 2003-07-11 | Células indutoras de aceitação de transplante de origem monocìtica e sua preparação e aplicação |
| PT05009317T PT1557462E (pt) | 2002-07-12 | 2003-07-11 | Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização |
| DE60320009T DE60320009T2 (de) | 2002-07-12 | 2003-07-11 | Transplantat-Akzeptanz-induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung |
| AT05009317T ATE390480T1 (de) | 2002-07-12 | 2003-07-11 | Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung |
| JP2004520603A JP2005532803A (ja) | 2002-07-12 | 2003-07-11 | 単球由来の移植片受容誘導細胞ならびにその調製およびその使用 |
| SI200331240T SI1557462T1 (sl) | 2002-07-12 | 2003-07-11 | Celice monocitnega izvora, ki inducirajo sprejemljivost transplantata, kot tudi njihova priprava in uporaba |
| CA002492383A CA2492383A1 (en) | 2002-07-12 | 2003-07-11 | Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| EP05009317A EP1557462B1 (en) | 2002-07-12 | 2003-07-11 | Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| HK05104363.6A HK1071586B (en) | 2002-07-12 | 2003-07-11 | Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| SI200330146T SI1492869T1 (sl) | 2002-07-12 | 2003-07-11 | Celice monocitnega izvora, ki inducirajo sprejemanje transplantata, in njihova priprava in uporaba |
| PCT/EP2003/007551 WO2004007701A1 (en) | 2002-07-12 | 2003-07-11 | Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| AT03763823T ATE309331T1 (de) | 2002-07-12 | 2003-07-11 | Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung |
| AU2003250939A AU2003250939B2 (en) | 2002-07-12 | 2003-07-11 | Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| ES03763823T ES2252696T3 (es) | 2002-07-12 | 2003-07-11 | Celulas inductoras de aceptacion de trasplantes de origen monocitico y su preparacion y uso. |
| ES05009317T ES2304647T3 (es) | 2002-07-12 | 2003-07-11 | Celulas inductoras de aceptacion de trasplantes de origen monocitico y su preparacion y uso. |
| EP03763823A EP1492869B9 (en) | 2002-07-12 | 2003-07-11 | Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| RU2005103627/13A RU2370535C2 (ru) | 2002-07-12 | 2003-07-11 | Способ получения индуцирующих воспринимаемость трансплантата клеток моноцитарного происхождения, способ получения фармацевтической композиции для подавления реакций отторжения трансплантата, индуцирующие воспринимаемость трансплантата клетки моноцитарного происхождения, клеточный препарат для индукции воспринимаемости трансплантата, фармацевтическая композиция для подавления реакций отторжения трансплантата, применение индуцирующих воспринимаемость трансплантата клеток (варианты), способ получения и/или размножения регуляторных т-лимфоцитов, гибридомная клеточная линия, антитело и применение антитела |
| PT04701001T PT1644484E (pt) | 2002-07-12 | 2004-01-09 | Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas |
| ES04701001T ES2310711T3 (es) | 2002-07-12 | 2004-01-09 | Celulas autologas inductoras de la auto-tolerancia de origen monocitico y su uso en preparaciones farmaceuticas. |
| SI200430965T SI1644484T1 (sl) | 2002-07-12 | 2004-01-09 | Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah |
| IL166021A IL166021A (en) | 2002-07-12 | 2004-12-28 | Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| ZA200501054A ZA200501054B (en) | 2002-07-12 | 2005-02-04 | Transplant acceptance inducing cells of monocytic origin and their preparation and use. |
| NO20050719A NO20050719L (no) | 2002-07-12 | 2005-02-10 | Transplantat akseptinduserende celler av monocytisk opprinnelse og deres fremstilling og anvendelse |
| IL172854A IL172854A0 (en) | 2002-07-12 | 2005-12-27 | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations |
| ZA200601074A ZA200601074B (en) | 2002-07-12 | 2006-02-07 | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10231655A DE10231655A1 (de) | 2002-07-12 | 2002-07-12 | Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10231655A1 true DE10231655A1 (de) | 2004-02-26 |
Family
ID=30009939
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10231655A Ceased DE10231655A1 (de) | 2002-07-12 | 2002-07-12 | Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung |
| DE60302231T Expired - Fee Related DE60302231T2 (de) | 2002-07-12 | 2003-07-11 | Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung |
| DE60320009T Expired - Fee Related DE60320009T2 (de) | 2002-07-12 | 2003-07-11 | Transplantat-Akzeptanz-induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60302231T Expired - Fee Related DE60302231T2 (de) | 2002-07-12 | 2003-07-11 | Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung |
| DE60320009T Expired - Fee Related DE60320009T2 (de) | 2002-07-12 | 2003-07-11 | Transplantat-Akzeptanz-induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20060286670A1 (enExample) |
| EP (2) | EP1557462B1 (enExample) |
| JP (1) | JP2005532803A (enExample) |
| CN (1) | CN100523176C (enExample) |
| AT (2) | ATE390480T1 (enExample) |
| AU (1) | AU2003250939B2 (enExample) |
| BR (1) | BR0312693A (enExample) |
| CA (1) | CA2492383A1 (enExample) |
| DE (3) | DE10231655A1 (enExample) |
| DK (2) | DK1557462T3 (enExample) |
| ES (3) | ES2304647T3 (enExample) |
| IL (3) | IL166021A0 (enExample) |
| NO (1) | NO20050719L (enExample) |
| PT (2) | PT1557462E (enExample) |
| RU (1) | RU2370535C2 (enExample) |
| SI (3) | SI1492869T1 (enExample) |
| WO (1) | WO2004007701A1 (enExample) |
| ZA (2) | ZA200501054B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8603809B2 (en) | 2003-06-23 | 2013-12-10 | Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung E. V. | Isolated adult pluripotent stem cells and methods for isolating and cultivating thereof |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1644484B1 (en) * | 2003-07-11 | 2008-09-17 | Blasticon Biotechnologische Forschung GmbH | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations |
| EP1928479B1 (en) * | 2005-08-24 | 2016-06-08 | Yeda Research And Development Co., Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
| WO2007043641A1 (ja) | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
| BRPI0617664B8 (pt) | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| WO2007116962A1 (ja) | 2006-04-07 | 2007-10-18 | Osaka University | 筋再生促進剤 |
| CN101646459B (zh) | 2007-01-23 | 2014-02-12 | 国立大学法人信州大学 | 慢性排斥反应抑制剂 |
| JP5544290B2 (ja) | 2008-06-05 | 2014-07-09 | 独立行政法人国立がん研究センター | 神経浸潤抑制剤 |
| ES2615861T3 (es) * | 2008-10-30 | 2017-06-08 | Yeda Research And Development Company Ltd. | Células T de memoria central anti-terceros, métodos de producción de las mismas y uso de las mismas en trasplante y tratamiento de enfermedades |
| JP5436905B2 (ja) * | 2009-03-26 | 2014-03-05 | テルモ株式会社 | シート状細胞培養物の製造方法 |
| JP5667357B2 (ja) * | 2009-11-30 | 2015-02-12 | テルモ株式会社 | シート状細胞培養物の製造方法 |
| CN101812428A (zh) * | 2010-04-26 | 2010-08-25 | 西北农林科技大学 | 一种乳腺上皮细胞的组织块种植方法 |
| HUE060454T2 (hu) | 2010-05-28 | 2023-03-28 | Chugai Pharmaceutical Co Ltd | Daganatellenes T-sejt-választ fokozó szer |
| DE102011004335A1 (de) | 2011-02-17 | 2012-08-23 | Thomas Grammel | Verfahren zur Herstellung eines Vakzins |
| RU2508924C1 (ru) * | 2013-02-21 | 2014-03-10 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" | Способ профилактики и лечения отторжения почечного трансплантата |
| JP5727665B2 (ja) * | 2014-12-11 | 2015-06-03 | テルモ株式会社 | シート状細胞培養物の製造方法 |
| JP5893786B2 (ja) * | 2015-04-02 | 2016-03-23 | テルモ株式会社 | シート状細胞培養物の製造方法 |
| KR102769850B1 (ko) * | 2015-07-03 | 2025-02-20 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 조절 t 세포를 수득하는 방법 및 이의 용도 |
| JP6903866B2 (ja) * | 2016-01-27 | 2021-07-14 | 国立大学法人 熊本大学 | 血液由来単球の増殖誘導方法 |
| JP6140322B2 (ja) * | 2016-02-24 | 2017-05-31 | テルモ株式会社 | シート状細胞培養物の製造方法 |
| JP6490738B2 (ja) * | 2017-04-28 | 2019-03-27 | テルモ株式会社 | シート状細胞培養物の製造方法 |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| EP3698808B1 (en) | 2017-10-20 | 2025-01-01 | Hyogo College Of Medicine | Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
| JP6657452B2 (ja) * | 2019-02-27 | 2020-03-04 | テルモ株式会社 | シート状細胞培養物の製造方法 |
| JP7002497B2 (ja) * | 2019-06-20 | 2022-01-20 | テルモ株式会社 | シート状細胞培養物の製造方法 |
| JP6872051B2 (ja) * | 2020-02-05 | 2021-05-19 | テルモ株式会社 | シート状細胞培養物の製造方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766920A (en) * | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| GB9502022D0 (en) * | 1995-02-02 | 1995-03-22 | Abuljadayel Ilham M S | A method for preparing lymphohaematopoietic progenitor cells |
| US9068164B1 (en) * | 1995-02-02 | 2015-06-30 | Tristem Trading (Cyprus) Limited | Method of preparing an undifferentiated cell |
| US7410773B2 (en) * | 1995-02-02 | 2008-08-12 | Ghazi Jaswinder Dhoot | Method of preparing an undifferentiated cell |
| US7112440B2 (en) * | 1995-02-02 | 2006-09-26 | Ghazi Jaswinder Dhoot | Method of increasing the relative number of CD45 low cells in a cell population |
| ES2201177T3 (es) * | 1995-03-08 | 2004-03-16 | The Scripps Research Institute | Sistema de presentacion de antigenos y activacion de celulas-t. |
| WO1998053048A1 (en) * | 1997-05-21 | 1998-11-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells |
| NL1017973C2 (nl) * | 2000-05-10 | 2002-11-08 | Tristem Trading Cyprus Ltd | Inrichting. |
| AU2002224851A1 (en) * | 2000-11-14 | 2002-05-27 | Universite Libre De Bruxelles | Generation and use of dendritic cells |
| TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
-
2002
- 2002-07-12 DE DE10231655A patent/DE10231655A1/de not_active Ceased
-
2003
- 2003-07-11 US US10/520,931 patent/US20060286670A1/en not_active Abandoned
- 2003-07-11 AU AU2003250939A patent/AU2003250939B2/en not_active Ceased
- 2003-07-11 EP EP05009317A patent/EP1557462B1/en not_active Expired - Lifetime
- 2003-07-11 AT AT05009317T patent/ATE390480T1/de not_active IP Right Cessation
- 2003-07-11 BR BR0312693-5A patent/BR0312693A/pt not_active IP Right Cessation
- 2003-07-11 SI SI200330146T patent/SI1492869T1/sl unknown
- 2003-07-11 ES ES05009317T patent/ES2304647T3/es not_active Expired - Lifetime
- 2003-07-11 CA CA002492383A patent/CA2492383A1/en not_active Abandoned
- 2003-07-11 DE DE60302231T patent/DE60302231T2/de not_active Expired - Fee Related
- 2003-07-11 PT PT05009317T patent/PT1557462E/pt unknown
- 2003-07-11 SI SI200331240T patent/SI1557462T1/sl unknown
- 2003-07-11 RU RU2005103627/13A patent/RU2370535C2/ru not_active IP Right Cessation
- 2003-07-11 ES ES03763823T patent/ES2252696T3/es not_active Expired - Lifetime
- 2003-07-11 AT AT03763823T patent/ATE309331T1/de not_active IP Right Cessation
- 2003-07-11 WO PCT/EP2003/007551 patent/WO2004007701A1/en not_active Ceased
- 2003-07-11 DE DE60320009T patent/DE60320009T2/de not_active Expired - Fee Related
- 2003-07-11 EP EP03763823A patent/EP1492869B9/en not_active Expired - Lifetime
- 2003-07-11 IL IL16602103A patent/IL166021A0/xx unknown
- 2003-07-11 DK DK05009317T patent/DK1557462T3/da active
- 2003-07-11 CN CNB038215748A patent/CN100523176C/zh not_active Expired - Fee Related
- 2003-07-11 DK DK03763823T patent/DK1492869T3/da active
- 2003-07-11 JP JP2004520603A patent/JP2005532803A/ja active Pending
-
2004
- 2004-01-09 SI SI200430965T patent/SI1644484T1/sl unknown
- 2004-01-09 ES ES04701001T patent/ES2310711T3/es not_active Expired - Lifetime
- 2004-01-09 PT PT04701001T patent/PT1644484E/pt unknown
- 2004-12-28 IL IL166021A patent/IL166021A/en not_active IP Right Cessation
-
2005
- 2005-02-04 ZA ZA200501054A patent/ZA200501054B/xx unknown
- 2005-02-10 NO NO20050719A patent/NO20050719L/no not_active Application Discontinuation
- 2005-12-27 IL IL172854A patent/IL172854A0/en unknown
-
2006
- 2006-02-07 ZA ZA200601074A patent/ZA200601074B/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8603809B2 (en) | 2003-06-23 | 2013-12-10 | Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung E. V. | Isolated adult pluripotent stem cells and methods for isolating and cultivating thereof |
| US9206393B2 (en) | 2003-06-23 | 2015-12-08 | Fraunhofer Gesellschaft Zur Forderung De Angewandten Forschung E.V. | Isolated adult pluripotent stem cells and methods for isolating and cultivating thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60302231T2 (de) | Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung | |
| DE69929681T2 (de) | Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen | |
| DE60026561T2 (de) | Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen | |
| DE69715611T2 (de) | Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen | |
| KR101578591B1 (ko) | 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
| DE69431107T2 (de) | Die erzeugung von toleranz gegen fremdtransplantate durch tolerogenese mit hilfe von ersatzlebewesen | |
| DE19833476A1 (de) | Genetisch modifizierte CD34-Negative, adhärent wachsende Stammzellen und deren Verwendung in der Gentherapie | |
| DE19813759C1 (de) | Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort | |
| Im et al. | Induction of mixed chimerism using combinatory cell-based immune modulation with mesenchymal stem cells and regulatory T cells for solid-organ transplant tolerance | |
| WO2014069655A1 (ja) | 免疫寛容誘導剤 | |
| DE69725317T2 (de) | Implantierbare agarose-kollagenkügelchen enthaltende zellen, die ein diffusionsfähiges biologisches produkt bilden und ihre verwendung | |
| WO2002040640A2 (en) | Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc) | |
| DE69835591T2 (de) | Induktoren für immuntoleranz | |
| DE69633494T2 (de) | Verfahren zur verhinderung von transplantatabstossung | |
| DE69012105T2 (de) | Proliferation von cd4-lymfocyten. | |
| EP1370641B1 (de) | Verwendung von stammzellen und cd6-depletierten stammzellen zur toleranzinduktion gegenüber allogenen transplantaten und/oder zur leukämiebehandlung | |
| US20040228845A1 (en) | Methods of using CD8+/TCR- facilitating cells (FC) for the engraftment of purified hematopoietic stem cells (HSC) | |
| DE69532557T2 (de) | Zubereitung enthaltend Glykane übereinstimmend mit Transferrin Glykaner als aktives Prinzip für die Induktion der Immuntoleranz gegen Antigene | |
| KR101694554B1 (ko) | 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물 | |
| US20070148141A1 (en) | Method of using hepatic progenitors in treating liver dysfunction | |
| DE69431184T2 (de) | Ein thymus-fremdtransplantat | |
| DE60106748T2 (de) | Toleranzinduzierendes gewebekonstrukt und organ zusammengesetzt aus thymus und knochenmark | |
| DE69816812T2 (de) | Non myeloablative therapie für toleranzinduktion | |
| Hess et al. | Immunosuppression by succinylacetone. II. Prevention of graft-vs-host disease. | |
| DE4017818C2 (de) | Verfahren zur Überprüfung von Substanzen auf ihre Wirksamkeit als paf-Acether-Antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8131 | Rejection |